सत्यमेव जयते

Government of India
Central Drugs Standard Control Organisation(Headquarter)
(Directorate General of Health Services)
FDA Bhavan, ITO, Kotla Road
New Delhi - 110002 (Delhi)
Phone No.: 91-11-23216367
Fax No.: 91-11-23236973
E-Mail: dci@nic.in

File No. BIO/CT/24/000016 Dated 20-09-2024

To,

M/s Enzene Biosciences Limited,
Plot No. A 22, A/1/2 Chakan Industrial Area,
Phase 2, Khalumbre Chakan,
Pune, Maharashtra (India) – 410501

Subject: Application for grant of permission to conduct clinical trial entitled -"A Phase IV, open label, single-arm, multi-center clinical study to evaluate the safety and efficacy of Biosimilar Ranibizumab (ENZ105) in patients with Neovascular (Wet) Age related Macular Degeneration (AMD)" vide Protocol No.: ALK34/ENZ105-RANI2 Version:1.0, Date: 08-JAN-2024 - regarding.

Ref. No.: Your Application No. BIO/CT04/FF/2024/41868 dated12-Feb-2024.

Sir,

With reference to your application No. BIO/CT04/FF/2024/41868 dated 12-Feb-2024, please find enclosed herewith the permission in Form CT-06 for conduct of subject clinical trial under the provisions of New Drugs and Clinical Trial Rules, 2019.

The permission granted by the Central Licensing Authority to conduct clinical trial under this Chapter shall be subject to following conditions, namely:

(I) Clinical trial at each site shall be initiated after approval of the clinical trial protocol and other related documents by the Ethics Committee of that site, registered with the Central Licensing Authority under rule 8.

(II) Where a clinical trial site does not have its own Ethics Committee, clinical trial at that site may be initiated after obtaining approval of the protocol from the Ethics Committee of another trial site; or an independent Ethics Committee for clinical trial constituted in accordance with the provisions of rule 7:

Provided that the approving Ethics Committee for clinical trial shall in such case be responsible for the study at the trial site or the centre, as the case may be:

Provided further that the approving Ethics Committee and the clinical trial site or the bioavailability and bioequivalence centre, as the case may be, shall be located within the same city or within a radius of 50 kms of the clinical trial site;

(III) In case an ethics committee of a clinical trial site rejects the approval of the protocol, the details of the same shall be submitted to the Central Licensing Authority prior to seeking approval of another Ethics Committee for the protocol for conduct of the clinical trial at the same site;

(IV) The Central Licensing Authority shall be informed about the approval granted by the Ethics Committee within a period of fifteen working days of the grant of such approval;

(V) Clinical trial shall be registered with the Clinical Trial Registry of India maintained by the Indian Council of Medical Research before enrolling the first subject for the trial.

(VI) Clinical trial shall be conducted in accordance with the approved clinical trial protocol and other related documents and as per requirements of Good Clinical Practices Guidelines and the provisions of these rules;

(VII) Status of enrolment of the trial subjects shall be submitted to the Central Licensing Authority on quarterly basis or as appropriate as per the duration of treatment in accordance with the approved clinical trial protocol, whichever is earlier;

(VIII) Six monthly status report of each clinical trial, as to whether it is ongoing, completed or terminated, shall be submitted to the Central Licensing Authority electronically in the SUGAM portal.

(IX) In case of termination of any clinical trial the detailed reasons for such termination shall be communicated to the Central Licensing Authority within thirty working days of such termination.

(X) Any report of serious adverse event occurring during clinical trial to a subject of clinical trial, shall, after due analysis, be forwarded to the Central Licensing Authority, the chairperson of the Ethics Committee and the institute where the trial has been conducted within fourteen days of its occurrence as per Table 5 of the Third Schedule and in compliance with the procedures as specified in Chapter VI.

(XI) In case of injury during clinical trial to the subject of such trial, complete medical management and compensation shall be provided in accordance with Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licensing Authority within thirty working days of the receipt of order issued by Central Licensing Authority in accordance with the provisions of the said Chapter.

(XII) In case of clinical trial related death or permanent disability of any subject of such trial during the trial, compensation shall be provided in accordance with Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licensing Authority within thirty working days of receipt of the order issued by the Central Licensing Authority in accordance with the provisions of the said Chapter.

(XIII) The premises of the sponsor including his representatives and clinical trial sites, shall be open for inspection by officers of the Central Licensing Authority who may be accompanied by officers of the State Licensing Authority or outside experts as authorized by the Central Licensing Authority, to verify compliance of the requirements of these rules and Good Clinical Practices Guidelines, to inspect, search and seize any record, result, document, investigational product, related to clinical trial and furnish reply to query raised by the said officer in relation to clinical trial.

(XIV) The laboratory owned by any person or a company or any other legal entity and utilised by that person to whom permission for clinical trial has been granted used for research and development, shall be deemed to be registered with the Central Licensing Authority and may be used for test or analysis of any drug for and on behalf of Central Licensing Authority.

(XV) The Central Licensing Authority may, if considered necessary, impose any other condition in writing with justification, in respect of specific clinical trials, regarding the objective, design, subject population, subject eligibility, assessment, conduct and treatment of such specific clinical trial.

(XVI) The sponsor and the investigator shall maintain the data integrity of the data generated during clinical trial.

RAJEEV SINGH RAGHUVANSHI

Digitally signed by RAJEEV SINGH RAGHUVANSHI
DN: c=IN, o=CENTRAL DRUGS STANDARD CONTROL ORGANISATION, ou=CENTRAL DRUGS STANDARD CONTROL ORGANISATION, 2.5.4.20=[illegible], postalCode=110002, st=Delhi, serialNumber=657f5e47d940985d8f03bdc902d0e1fe73cfa12a1a126ea94fa5701124a19013, cn=RAJEEV SINGH RAGHUVANSHI
Date: 2024.09.20 16:50:01 +05'30'

(Dr. Rajeev Singh Raghuvanshi)
Drugs Controller General (India)
Licensing Authority

FORM CT-06

(See rules 22, 25, 26, 29 and 30)

PERMISSION TO CONDUCT CLINICAL TRIAL OF NEW DRUG OR INVESTIGATIONAL NEW DRUG

The Central Licensing Authority hereby permits **M/s Enzene Biosciences Limited, Pune, Plot No. A 22, A/1/2 Chakan Industrial Area, Phase 2, Khalumbre Chakan, Pune (India)- 410501 Telephone No.: 02135614300 FAX: 2030674620 E-Mail: HARISH.SHANDILYA@ENZENE.COM** to conduct clinical trial of new drug or investigational new drug as per clinical study entitled **"A Phase IV, open label, single-arm, multi-center clinical study to evaluate the safety and efficacy of Biosimilar Ranibizumab (ENZ105) in patients with Neovascular (Wet) Agerelated Macular Degeneration (AMD)"** vide **Protocol No.: ALK34/ENZ105-RANI2 Version:1.0, Date: 08-JAN-2024** in the below mentioned clinical trial sites.

2. Details of new drug and clinical trial site [as per Annexure].

3. This permission is subject to the conditions prescribed in part A of Chapter V of the New Drugs and Clinical Trials Rules, 2019 under the Drugs and Cosmetics Act, 1940.

Place: New Delhi
Date: 20-Sep-2024

RAJEEV SINGH RAGHUVANSHI

Digitally signed by RAJEEV SINGH RAGHUVANSHI
DN: c=IN, o=CENTRAL DRUGS STANDARD CONTROL ORGANISATION, ou=CENTRAL DRUGS STANDARD CONTROL ORGANISATION, 2.5.4.20=42d7189b1c0981bb5a263a4a73d025ff4b11b680a91f087734804 00a43ee361b, postalCode=110002, st=Delhi, serialNumber=6575e47d940985d8f03bdc902d0e1fe73cfa12a1a126ea94fa570112 4a19013, cn=RAJEEV SINGH RAGHUVANSHI
Date: 2024.09.20 16:50:11 +05'30'

(Dr. Rajeev Singh Raghuvanshi)
Drugs Controller General (India)
Central Licensing Authority

Annexure:

Details of new drug or investigational new drug:

<table>
<tr><td>Names of the new drug or investigational new drug:</td><td>Ranibizumab Injection 10mg/ml single use vial (r-DNA origin)
One vial of Ranibizumab injection, one syringe, two needles (Filter Needle and 30G Needle)</td></tr>
<tr><td>Dosage form:</td><td>Solution for injection in vial</td></tr>
<tr><td>Therapeutic Class</td><td>Anti VEGF</td></tr>
<tr><td>Composition:</td><td>Each 1ml of vial contains:
<table>
<tr><th>Name of Ingredients</th><th>Quantity (mg/ml)</th></tr>
<tr><td>Ranibizumab Drug substance, In-House</td><td>10.0</td></tr>
<tr><td>Polysorbate 20 IP</td><td>0.1</td></tr>
<tr><td>L-Histidine EP</td><td>0.321</td></tr>
<tr><td>L-Histidine hydrochloride monohydrate EP</td><td>1.662</td></tr>
<tr><td>α, α Trehalose dehydrate EP</td><td>100.0</td></tr>
<tr><td>Water for Injection (WFI) IP</td><td>q.s. to 1.0 ml</td></tr>
</table></td></tr>
<tr><td>Indication:</td><td>Neovascular Age related Macular Degeneration</td></tr>
</table>

Details of clinical trial site(s):

S.No.	Name and Address of Clinical Trial Site(s)	Ethics Committee Details	Name of Principal Investigator
1.	Sankar Kartik Netralaya, 14/73, First Floor, Civil Lines, Near Merchant Chamber, Opposite dayanand Girls PG College, VIP Road, Kanpur, Uttar Pradesh-208001	Ethics Committee, Brij Medical Centre, Brij Medical Private Limited, Panki, Kanpur- 208020, Uttar Pradesh, India EC Reg. No.: ECR/642/Inst/UP/2014/RR-20	Dr. Manish Saxena
2.	Amrita Institute of Medical Science, Ponekkara Road, P.O., Edapally, Kochi, Ernakulam, Kerala- 682041	Institutional Ethics Committee Amrita Institute of Medical Sciences AIMS-Ponekkara Kochi Edappally Ernakulam Kerala-682041, India EC Reg. No.: ECR/129/Inst/KL/2013/RR-19	Dr. Gopal S Pillai
3.	Drishtipunj Eye Hospital, Vashikunj Appartment, Bailey Road, near Zee Saheb Super Market, Saguna More, Danapur, Bihar- 801503 India	Institutional Ethics Committee, BSL Eye car, Road no. 2B, Rajendra Nagar, Patna, Bihar-800020, India EC Reg. No.: ECR/1328/Inst/BR/2019	Dr. Satya Prakash Tiwary

4.	Disha Eye Hospital, 88 (63A), Ghoshpara Road, Kolkata-700120, West Bengal, India	Disha Eye Hospital Private Limited, Ethics Committee, 88(63A), Ghoshpara Road, Barrackpore, North 24, Parganas, Kolkata, West Bengal-700120. EC Reg. No.: ECR/846/Inst/WB/2016/RR-19	Dr. Debdulal Chakraborty
5.	JPM Rotary Club of Cuttack Eye Hospital and Research Institute, CDA, Sector-VI, Market Nagar, Cuttack-753014, Odisha, India	Institutional Ethics Committee JPM Rotary Eye Hospital JPM Rotary Eye Hospital CDA, Sector- VI, Market Nagar Cuttack, Orissa- 753014 India EC Reg. No.: ECR/856/Inst/OR/2016/RR-20	Dr Santosh Mahapatra
6.	GMERS Medical College and Civil Hospital Sola, Nr. Gujarat High court, SG Highway, Sola, Ahmedabad-380060, Gujarat	Institutional Ethics Committee, GMERS medical college, Sola SG Highway, near Gujarat High Court, Ahmedabad, Gujarat-380061 India EC Reg. No.: ECR/404/Inst/GJ/2013/RR-20	Dr. Deepika Singhal
7.	Kar Vision Eye Hospital, 10, Janpath Road, Satya Nagar, Bhubaneswar, Odisha-751007, India	Kar Vision Institutional Ethics Committee, Kar Vision Eye Hospital, 10, Janpath Road, Satya Nagar, Bhubaneswar, Odisha- 751007, India EC Reg. No.: ECR/1630/Inst/OD/2021	Dr. Sanghmitra Kanungo
8.	M & J Western Regional Institute of ophthalmology, Asarwa, Ahmedabad-380016, Gujarat, India.	Institutional Ethics Committee B.J. Medical college and civil hospital office of medical Superintendent civil hospital Ahemdabad, Gujarat- 380016, India EC Reg. No.: ECR/72/Inst/GJ/2013/RR-19	Dr. Neha Desai
9.	Netralaya Superspeciality hospital, 1st Floor, Kaydee House, above Union Bank of India, Opposite Gujarat Gas, Parimal Garden Cross road, CG Road, Ahmedabad-380006, Gujarat, India	Sangini Hospital Ethics Committee, C/o. Sangini Hospital, 1st floor, Santorini square, B/H Abhishree Complex, Opp. Star Bazar, Near Jodhpur crossroad, Satellite, Ahemdabad-380015,Gujarat. EC Reg. No.: ECR/147/Inst/GJ/2013/RR-19	Dr. Parth Rana